IP Library › Granted Patent US 9,834,596
Granted Patent B2
US 9,834,596 · App. 14/412,309 · Granted Dec 5, 2017

Antibodies to tau

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,596
App. No.
14/412,309
Granted
Dec 5, 2017
Kind
B2
Abstract

This invention relates to antibodies to tau and methods of use thereof.

Claims (16)

1. An isolated monoclonal anti-tau antibody, wherein the antibody comprises:

a light chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 16, a CDR2 of amino acid sequence SEQ ID NO: 17, and a CDR3 of amino acid sequence SEQ ID NO: 18, and

a heavy chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 19, a CDR2 of amino acid sequence SEQ ID NO: 20, and a CDR3 of amino acid sequence SEQ ID NO: 21.

2. The isolated monoclonal anti-tau antibody of claim 1 , wherein the antibody specifically binds human tau with an Affinity of Interaction (KD) of 0.1 pM to 10 nM.

3. The isolated monoclonal anti-tau antibody of claim 1 , wherein the antibody specifically binds human tau with an Affinity of Interaction (KD) of 0.1 pM to 1 nM.

4. The isolated monoclonal anti-tau antibody of claim 1 , wherein the antibody specifically binds human tau and does not bind mouse tau.

5. The isolated monoclonal anti-tau antibody of claim 1 , wherein the antibody is a humanized antibody.

6. The isolated monoclonal anti-tau antibody of claim 1 , wherein the antibody is specifically able to block tau seeding activity in a cellular tau aggregation assay.

7. The isolated monoclonal anti-tau antibody of claim 1 , wherein the antibody is a chimeric antibody.

8. The isolated monoclonal anti-tau antibody of claim 1 , wherein the light chain variable region and the heavy chain variable region comprise framework regions.

9. The isolated monoclonal anti-tau antibody of claim 8 , wherein the antibody is an IgG isotype.

10. The isolated monoclonal anti-tau antibody of claim 9 , wherein the antibody is a chimeric antibody.

11. The isolated monoclonal anti-tau antibody of claim 9 , wherein the antibody is a humanized antibody.

12. The isolated monoclonal anti-tau antibody of claim 9 , wherein the antibody is an IgG4 isotype.

13. The isolated monoclonal anti-tau antibody of claim 12 , wherein the antibody is a chimeric antibody.

14. The isolated monoclonal anti-tau antibody of claim 12 , wherein the antibody is a humanized antibody.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 11, 2016
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039301/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2015
From: HOLTZMAN, DAVID; JIANG, HONG; DIAMOND, MARC; HOLMES, BRANDON; KFOURY, NAJLA
To: WASHINGTON UNIVERSITY
Reel/Frame 034908/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2015
From: HOLTZMAN, DAVID; JIANG, HONG; DIAMOND, MARC; HOLMES, BRANDON; KFOURY, NAJLA
To: WASHINGTON UNIVERSITY
Reel/Frame 034829/0848 →